Refractory and relapsed cancer patients often develop resistance mechanisms associated with an immunosuppressive tumor microenvironment (TME). Indeed, the TME is critically involved not only in tumor growth, invasion and dissemination,… Click to show full abstract
Refractory and relapsed cancer patients often develop resistance mechanisms associated with an immunosuppressive tumor microenvironment (TME). Indeed, the TME is critically involved not only in tumor growth, invasion and dissemination, but in immune editing and resistance to different therapies both conventional and biological. Innate myeloid cells such as monocytes, macrophages, neutrophils, and a diverse set of cells, sometime called myeloid derived suppressor cells (MDSCs) may drive both local and systemic immunosuppression. These cells, however, possess novel molecules and functions that could be targeted to fight against cancer making them potential candidates for development of second-generation immunotherapy approaches. The aim of this article collection is to provide a comprehensive overview of the different myeloid subsets in the TME, and to describe recent developments and approaches targeting myeloid cells to enhance anti-tumor immunity and the clinical efficacy of standard-of-care cancer drugs.
               
Click one of the above tabs to view related content.